Pfizer (PFE) has decided to divest its equity holding in ViiV Healthcare, an HIV treatment maker majority owned by GSK (GSK), while Japanese drugmaker Shionogi (SGIOY) (SGIOF) has increased its stake.
Under the agreement expected to close in Q1 2026, the New York-based pharma giant’s 11.7% stake in ViiV Healthcare will be replaced by an investment from Shionogi (SGIOY).
Once the new shareholding structure takes effect, Pfizer (PFE) will no longer have an equity interest in ViiV, Shionogi (SGIOF) will have its stake increased to 21.7%, and GSK (GSK) will retain its 78.3% ownership unchanged.
As part of the deal, ViiV Healthcare will issue new shares to Shionogi (SGIOF) for $2.125B and cancel Pfizer’s (PFE) holding in the company, generating $1.875M for the U.S.-based vaccine maker. Meanwhile, GSK (GSK) will be entitled to a special dividend of $0.250B payable in sterling pounds.
